TY - JOUR
T1 - A pituitary metastasis, an adenoma and potential hypophysitis
T2 - A case report of tumour to tumour metastasis in the pituitary
AU - Castle-Kirszbaum, Mendel
AU - Beng Phung, Teik
AU - Luen, Stephen J.
AU - Rimmer, Joanne
AU - Chandra, Ronil V.
AU - Goldschlager, Tony
N1 - Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/11
Y1 - 2020/11
N2 - Tumour to tumour metastasis is a rare event, especially in the pituitary. Metastases to pituitary adenomas most commonly occurs in late stage disease, commonly presenting with visual field defects and adenohypophyseal dysfunction. The most frequent primary cancers are lung, breast and renal carcinoma which deposit most commonly in prolactinomas, somatotropinomas, gonadotropinomas. In nearly 40% of cases, sellar symptoms are the harbinger to the diagnosis of primary malignancy. The abnormal vascularity and growth promoting microenvironment of pituitary adenomas may encourage metastatic seeding and proliferation of these “collision tumours”. Here, we present a case of a breast carcinoma metastasis to a pituitary null-cell adenoma in the setting of immunotherapy. Infundibular thickening in the setting of immunotherapy is often ascribed to hypophysitis, but our case highlights that metastatic spread should be part of the differential diagnosis.
AB - Tumour to tumour metastasis is a rare event, especially in the pituitary. Metastases to pituitary adenomas most commonly occurs in late stage disease, commonly presenting with visual field defects and adenohypophyseal dysfunction. The most frequent primary cancers are lung, breast and renal carcinoma which deposit most commonly in prolactinomas, somatotropinomas, gonadotropinomas. In nearly 40% of cases, sellar symptoms are the harbinger to the diagnosis of primary malignancy. The abnormal vascularity and growth promoting microenvironment of pituitary adenomas may encourage metastatic seeding and proliferation of these “collision tumours”. Here, we present a case of a breast carcinoma metastasis to a pituitary null-cell adenoma in the setting of immunotherapy. Infundibular thickening in the setting of immunotherapy is often ascribed to hypophysitis, but our case highlights that metastatic spread should be part of the differential diagnosis.
UR - http://www.scopus.com/inward/record.url?scp=85092244935&partnerID=8YFLogxK
U2 - 10.1016/j.jocn.2020.09.033
DO - 10.1016/j.jocn.2020.09.033
M3 - Article
C2 - 33222908
AN - SCOPUS:85092244935
SN - 0967-5868
VL - 81
SP - 161
EP - 166
JO - Journal of Clinical Neuroscience
JF - Journal of Clinical Neuroscience
ER -